CoChat

Endothelial dysfunction in diabetic nephropathy: state of the art and potential significance for non-diabetic renal disease

Stehouwer, C. D. A. · 2004 · Nephrology Dialysis Transplantation
Cited by 128

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Much of the disease burden in diabetes occurs in patients with diabetic nephropathy, as they have the highest chance of developing cardiovascular disease as well as severe retinopathy and neuropathy [1]. Two issues appear crucial in stemming the epidemic of diabetic nephropathy and cardiovascular disease. One is the prevention of diabetes and the solution here from a public health point of view lies in the prevention of obesity. The other is improved understanding of the pathogenesis of renal and vascular disease in diabetes. Here, endothelial dysfunction (ED) is thought to play a key role. What is the state of the art with regard to this hypothesis? The endothelium is an important site of control of vascular functions [2]. Vascular endothelium normally decreases vascular tone; limits leukocyte adhesion and, thus, inflammatory activity in the vessel wall; regulates vascular permeability to nutrients, macromolecules and leukocytes; inhibits platelet adhesion and aggregation by producing prostacyclin, nitric oxide (NO) and ectonucleotidases; limits activation of the coagulation cascade by the thrombomodulin–protein C, heparan sulphate–antithrombin and tissue factor–tissue factor pathway inhibitor interactions; and regulates fibrinolysis by producing t-PA and its inhibitor, PAI-1. NO is a particularly important endothelium-derived mediator, because of its vasodilator, anti-platelet, anti-proliferative, anti-adhesive, permeability-decreasing and anti-inflammatory properties. ED can be considered present when endothelial properties have changed in a way that is inappropriate with regard to the preservation of organ function. For example, basement membrane synthesis may be altered, which can contribute to arterial stiffening and increased microvascular permeability; vascular tone and permeability may increase, which contributes to increased blood pressure and atherogenesis; and the endothelium may lose its antithrombotic and profibrinolytic properties and may instead acquire prothrombotic and antifibrinolytic properties. Such alterations (endothelial dysfunctions) do not necessarily occur simultaneously and may differ according to the nature of the injury and the intrinsic properties of the endothelium (e.g. venous vs arterial vs microvascular). Endothelial activation designates one specific type of ED characterized by (usually, inflammatory cytokine-induced) increased interactions with blood leukocytes, in which adhesion molecules and chemoattractants are essential. ED can be conceptualized as a transducer of atherogenic risk factors and is thought to play an important role both in the initiation and the progression of atherosclerosis. In this view, risk factors, such as oxidatively modified low-density lipoprotein cholesterol, smoking, hypertension, angiotensin-II and diabetes, initiate atherosclerosis through endothelial activation. The predilection to atherosclerosis of arterial branching points, bifurcations and convexities is explained by the fact that blood flow there is non-laminar or even turbulent and shear stress low or oscillatory, and that these conditions increase endothelial activation, effects that are enhanced by hypertension. These risk factors also have in common that NO availability is decreased through decreased production and (or) increased degradation, which furthers endothelial activation. Much of the above is based on experimental data. Testing these concepts in patients, above all, requires reliable measurements of endothelial function. Endothelial function cannot be measured directly in humans and, thus, indirect estimates are often used, which include endothelium-dependent vasodilation (EDV) and plasma levels of endothelium-derived regulatory mediators, such as NOx, endothelin, von Willebrand factor, soluble thrombomodulin, soluble adhesion molecules, t-PA and PAI-1. But are these tests valid estimates of ED? On the one hand, many cross-sectional studies have shown impaired EDV and high levels of endothelium-derived regulatory proteins in diseases that involve injury to the endothelium, such as atherothrombosis, pre-eclampsia and vasculitis, as well as in individuals with risk factors for atherothrombosis. Moreover, prospective studies have shown that individuals with impaired EDV and high levels of endothelium-derived regulatory proteins have an adverse cardiovascular prognosis [3–6]. On the other hand, the interpretation of these tests is not as straightforward as one would wish. Firstly, tests intended to estimate NO-mediated EDV in part measure effects of other endothelial vasodilators, such as prostacyclin and endothelium-derived hyperpolarizing factor. This has two consequences, which are not often emphasized, namely (a) that quantitatively normal EDV does not guarantee normal endothelial function, as (for example) less NO might be compensated by more endothelium-derived hyperpolarizing factor, and (b) that abnormal EDV in the presence of normal sodium nitroprusside-mediated vaso

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ndt/gfh015

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 128

Metadata

Authors
Stehouwer, C. D. A.
Venue
Nephrology Dialysis Transplantation
Published
2004-03-18
Volume
19
Issue
4
Pages
778-781
ISSN
  • 0931-0509 (ISSN-L)
  • 1460-2385
OpenAlex
W2107432878
Cited by
128
References
5
FWCI
3.61
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.